Search results

498 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
In development Remove In development filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Diagnostics guidance Remove Diagnostics guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Social care guidelines Remove Social care guidelines filter
Quality standards Remove Quality standards filter

Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

In development [GID-TA10377] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

In development [GID-TA10259] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147

In development [GID-TA10343] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Third molars (impacted) - prophylactic removal [ID898]

In development [GID-TAG525] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple sclerosis - sativex [ID387]

In development [GID-TAG368] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care

In development [GID-DT28] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID3775]

In development [GID-TA10636] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536]

In development [GID-TA10466] Expected publication date: 28 April 2021

Type

Technology appraisal guidance

Status

In development
Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]

In development [GID-TA10564] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

In development [GID-TA10363] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]

In development [GID-TA10609] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Sapropterin for treating phenylketonuria [ID1475]

In development [GID-TA10378] Expected publication date: 21 April 2021

Type

Technology appraisal guidance

Status

In development
Tebentafusp for treating metastatic HLA-A*02:01 positive uveal melanoma (ID1441)

In development [GID-TA10428] Expected publication date: 04 May 2022

Type

Technology appraisal guidance

Status

In development
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]

In development [GID-TA10587] Expected publication date: 02 June 2021

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509

In development [GID-TA10413] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]

In development [GID-TA10561] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]

In development [GID-TA10653] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]

In development [GID-TA10635] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

Technology appraisal [TA582] Published date: 24 May 2019

Type

Technology appraisal guidance

Status

In development
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

In development [GID-TA10254] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]

In development [GID-TA10399] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Luspatercept for treating beta-thalassaemia ID1554

In development [GID-TA10506] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Kidney transplantation (rejection) - everolimus [ID117]

In development [GID-TAG241] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Selumetinib for treating differentiated thyroid cancer ID1079

In development [GID-TA10207] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]

In development [GID-TA10249] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
NY-ESO-1 T-cells for treating synovial sarcoma ID1286

In development [GID-TA10205] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

In development [GID-TA10251] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Eltrombopag for untreated severe aplastic anaemia ID1198

In development [GID-TA10284] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

In development [GID-DT9] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

In development [GID-TA10311] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with epacadostat for untreated malignant melanoma ID1423

In development [GID-TA10330] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer ID1228

In development [GID-TA10203] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bevacizumab as monotherapy or in combination with lomustine for glioblastoma – second line [ID978]

In development [GID-TA10149] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bevacizumab for untreated malignant pleural mesothelioma (ID1183)

In development [GID-TA10197] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

In development [GID-DT14] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

In development [GID-TAG321] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]

In development [GID-TA10168] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Enzalutamide for the treatment of hormone refractory prostate cancer TA316

In development [GID-TA10267] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Leukaemia (chronic lymphocytic, relapsed) - ofatumumab (maintenance) [ID732]

In development [GID-TAG482] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Vemurafenib for treating resected BRAF V600 mutation-positive melanoma ID1250

In development [GID-TA10213] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

In development [GID-TAG507] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for previously treated multiple myeloma (ID1139)

In development [GID-TA10193] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

In development [GID-TAG511] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lymphoma (mantle cell, relapsed, refractory) - lenalidomide [ID739]

In development [GID-TAG508] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]

In development [GID-TA10018] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

In development [GID-TA10033] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

In development [GID-TA10099] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ATA129 for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus ID1203

In development [GID-TA10204] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Carotuximab with pazopanib for treating advanced angiosarcoma ID1503

In development [GID-TA10401] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Asunercept for treating glioblastoma [1301]

In development [GID-TA10227] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development